An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

NCT06379451 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: NKG2D Chimeric Antigen Receptor NK Cell Injection

Sponsor

Changzhou No.2 People's Hospital